Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, Netherlands.
Bioengineering and Telemedicine Group, Centro de Tecnología Biomédica, ETSI de Telecomunicación, Universidad Politécnica de Madrid, Parque Científico y Tecnológico de la UPM, Crta. M40, Km. 38, 28223 Pozuelo de Alarcón, Madrid, Spain.
Diabetes Res Clin Pract. 2024 Mar;209:111574. doi: 10.1016/j.diabres.2024.111574. Epub 2024 Feb 10.
This literature review had two objectives: to identify models for predicting the risk of coronary heart diseases in patients with diabetes (DM); and to assess model quality in terms of risk of bias (RoB) and applicability for the purpose of health technology assessment (HTA). We undertook a targeted review of journal articles published in English, Dutch, Chinese, or Spanish in 5 databases from 1st January 2016 to 18th December 2022, and searched three systematic reviews for the models published after 2012. We used PROBAST (Prediction model Risk Of Bias Assessment Tool) to assess RoB, and used findings from Betts et al. 2019, which summarized recommendations and criticisms of HTA agencies on cardiovascular risk prediction models, to assess model applicability for the purpose of HTA. As a result, 71 % and 67 % models reporting C-index showed good discrimination abilities (C-index >= 0.7). Of the 26 model studies and 30 models identified, only one model study showed low RoB in all domains, and no model was fully applicable for HTA. Since the major cause of high RoB is inappropriate use of analysis method, we advise clinicians to carefully examine the model performance declared by model developers, and to trust a model if all PROBAST domains except analysis show low RoB and at least one validation study conducted in the same setting (e.g. country) is available. Moreover, since general model applicability is not informative for HTA, novel adapted tools may need to be developed.
确定用于预测糖尿病(DM)患者患冠心病风险的模型;并根据偏倚风险(RoB)和适用性评估模型质量,以便进行卫生技术评估(HTA)。我们针对 2016 年 1 月 1 日至 2022 年 12 月 18 日期间在英文、荷兰文、中文或西班牙文 5 个数据库中发表的期刊文章进行了有针对性的综述,并对 2012 年后发表的模型进行了三项系统综述的检索。我们使用 PROBAST(预测模型风险偏倚评估工具)评估 RoB,并使用 Betts 等人的研究结果,该研究总结了 HTA 机构对心血管风险预测模型的建议和批评,评估模型在 HTA 中的适用性。结果显示,71%和 67%的报告 C 指数的模型显示出良好的区分能力(C 指数>=0.7)。在 26 项模型研究和 30 个模型中,只有一项模型研究在所有领域的 RoB 较低,没有一个模型完全适用于 HTA。由于 RoB 较高的主要原因是分析方法使用不当,我们建议临床医生仔细检查模型开发人员报告的模型性能,并在 PROBAST 除分析以外的所有领域显示 RoB 较低且至少有一项在相同环境(例如国家)进行的验证研究可用的情况下,信任该模型。此外,由于一般模型适用性对 HTA 没有信息性,可能需要开发新的适应性工具。